Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER Gene Therapy Office May Be Isolated In FDA Reorganization Plan

Executive Summary

FDA's proposed transfer of therapeutic biologic reviews to the drug center could negatively affect the newly created CBER Office of Cellular, Tissue & Gene Therapies, Acting Director Phillip Noguchi, MD, said
Advertisement

Related Content

CBER/CDER Consolidation Receives McClellan’s Blessing; Tensions Continue
CBER/CDER Consolidation Receives McClellan’s Blessing; Tensions Continue
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
CBER Gene Therapy Office To Be Established By Oct. 1
CBER Gene Therapy Office To Be Established By Oct. 1
Advertisement
UsernamePublicRestriction

Register

PS040718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel